Multiple Authorship

In their respective articles in the March 20, 1989, issue, Andrew Herxheimer (“Make Scientific Journals More Responsive—And Responsible”) and Murray Saffran [see above letter] are onto something important. We owe them and The Scientist a vote of thanks for articulating and publicizing it, and I hope it doesn’t end there. We tend to think that science is what goes on in laboratories, and we turn the spotlight on the poor experimentalist every time there is a question of

Written byTheodore Rockwell
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

In their respective articles in the March 20, 1989, issue, Andrew Herxheimer (“Make Scientific Journals More Responsive—And Responsible”) and Murray Saffran [see above letter] are onto something important. We owe them and The Scientist a vote of thanks for articulating and publicizing it, and I hope it doesn’t end there.

We tend to think that science is what goes on in laboratories, and we turn the spotlight on the poor experimentalist every time there is a question of fraud, misconduct, or inadequate research standards. (Theorists are a little harder to get a handle on, but they too are under the .gun.) We question their data keeping, their statistics, their procedures, and their honesty. But the scientific process also includes editors, reviewers, and grant-givers, and these important components of the scientific process operate almost without rules or accountability. Herxheimer and Saffran have suggested some good first steps, but much more is ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies